Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells

Neuropharmacology

Volumn 63, Issue 8, 2012, Pages 1368-1379

  Dragicevic, Natasa ^a,c   Delic, Vedad ^a   Cao, Chuanhai ^a,b   Copes, Neil ^a   Lin, Xiaoyang ^b   Mamcarz, Maggie ^a,c   Wang, Li ^a,b   Arendash, Gary W ^a,b   Bradshaw, Patrick C ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; Caffeine; Melatonin; Melatonin receptor; Mice; Mitochondrial; Phosphodiesterase

Indexed keywords

CAFFEINE; CYCLIC AMP; CYCLIC NUCLEOTIDE; MELATONIN; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN MITOCHONDRION; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIOXIDANTS; CAFFEINE; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM STIMULANTS; CYCLIC AMP; CYCLIC GMP; ENZYME-LINKED IMMUNOSORBENT ASSAY; MELATONIN; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, TRANSGENIC; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURONS; OXYGEN CONSUMPTION; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84867526964     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.08.018     Document Type: Article

References (86)

1. G.W. Arendash, and C. Cao Caffeine and coffee as therapeutics against Alzheimer's disease J. Alzheimers Dis. 20 Suppl. 1 2010 S117 S126
2. G.W. Arendash, T. Mori, C. Cao, M. Mamcarz, M. Runfeldt, A. Dickson, K. Rezai-Zadeh, J. Tan, B.A. Citron, X. Lin, V. Echeverria, and H. Potter Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice J. Alzheimers Dis. 17 2009 661 680
3. G.W. Arendash, W. Schleif, K. Rezai-Zadeh, E.K. Jackson, L.C. Zacharia, J.R. Cracchiolo, D. Shippy, and J. Tan Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production Neuroscience 142 2006 941 952
4. A.M. Babey, R.M. Palmour, and S.N. Young Caffeine and propranolol block the increase in rat pineal melatonin production produced by stimulation of adenosine receptors Neurosci. Lett. 176 1994 93 96
5. H. Babkoff, J. French, J. Whitmore, and R. Sutherlin Single-dose bright light and/or caffeine effect on nocturnal performance Aviat. Space Environ. Med. 73 2002 341 350
6. M.R. Brown, J.W. Geddes, and P.G. Sullivan Brain region-specific, age-related, alterations in mitochondrial responses to elevated calcium J. Bioenerg. Biomembr. 36 2004 401 406
7. P. Bubber, V. Haroutunian, G. Fisch, J.P. Blass, and G.E. Gibson Mitochondrial abnormalities in Alzheimer brain: mechanistic implications Ann. Neurol. 57 2005 695 703
8. M.J. Calkins, M. Manczak, P. Mao, U. Shirendeb, and P.H. Reddy Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease Hum. Mol. Genet. 20 2011 4515 4529
9. P.M. Canas, L.O. Porciuncula, G.M. Cunha, C.G. Silva, N.J. Machado, J.M. Oliveira, C.R. Oliveira, and R.A. Cunha Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway J. Neurosci. 29 2009 14741 14751
10. C. Cao, D.A. Loewenstein, X. Lin, C. Zhang, L. Wang, R. Duara, Y. Wu, A. Giannini, G. Bai, J. Cai, M. Greig, E. Schofield, R. Ashok, B. Small, H. Potter, and G.W. Arendash High blood caffeine levels in MCI linked to lack of progression to dementia J. Alzheimers Dis. 30 2012 559 572
11. R.K. Chaturvedi, and M.F. Beal Mitochondrial approaches for neuroprotection Ann. N. Y. Acad. Sci. 1147 2008 395 412
12. H.K. Chen, Z.S. Ji, S.E. Dodson, R.D. Miranda, C.I. Rosenblum, I.J. Reynolds, S.B. Freedman, K.H. Weisgraber, Y. Huang, and R.W. Mahley Apolipoprotein e4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease J. Biol. Chem. 286 2011 5215 5221
13. Y. Cheng, Z. Feng, Q.Z. Zhang, and J.T. Zhang Beneficial effects of melatonin in experimental models of Alzheimer disease Acta Pharmacol. Sin. 27 2006 129 139
14. D.A. Costa, J.R. Cracchiolo, A.D. Bachstetter, T.F. Hughes, K.R. Bales, S.M. Paul, R.F. Mervis, G.W. Arendash, and H. Potter Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms Neurobiol. Aging 28 2007 831 844
15. P.J. Crouch, R. Blake, J.A. Duce, G.D. Ciccotosto, Q.X. Li, K.J. Barnham, C.C. Curtain, R.A. Cherny, R. Cappai, T. Dyrks, C.L. Masters, and I.A. Trounce Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42 J. Neurosci. 25 2005 672 679
16. G.M. Cunha, P.M. Canas, C.S. Melo, J. Hockemeyer, C.E. Muller, C.R. Oliveira, and R.A. Cunha Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801 Exp. Neurol. 210 2008 776 781
17. O.P. Dall'Igna, P. Fett, M.W. Gomes, D.O. Souza, R.A. Cunha, and D.R. Lara Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice Exp. Neurol. 203 2007 241 245
18. N. Dragicevic, N. Copes, G. O'Neal-Moffitt, J. Jin, R. Buzzeo, M. Mamcarz, J. Tan, C. Cao, J.M. Olcese, G.W. Arendash, and P.C. Bradshaw Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling J. Pineal Res. 51 2011 75 86
19. N. Dragicevic, M. Mamcarz, Y. Zhu, R. Buzzeo, J. Tan, G.W. Arendash, and P.C. Bradshaw Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice J. Alzheimers Dis. 20 Suppl. 2 2010 S535 S550
20. H. Du, L. Guo, F. Fang, D. Chen, A.A. Sosunov, G.M. McKhann, Y. Yan, C. Wang, H. Zhang, J.D. Molkentin, F.J. Gunn-Moore, J.P. Vonsattel, O. Arancio, J.X. Chen, and S.D. Yan Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease Nat. Med. 14 2008 1097 1105
21. A. Eckert, K.L. Schulz, V. Rhein, and J. Gotz Convergence of amyloid-beta and tau pathologies on mitochondria in vivo Mol. Neurobiol. 41 2010 107 114
22. M. El Yacoubi, C. Ledent, J.F. Menard, M. Parmentier, J. Costentin, and J.M. Vaugeois The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors Br. J. Pharmacol. 129 2000 1465 1473
23. S.H. Francis, K.R. Sekhar, H. Ke, and J.D. Corbin Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds Handb Exp. Pharmacol. 200 2011 93 133
24. S.A. Frautschy, W. Hu, P. Kim, S.A. Miller, T. Chu, M.E. Harris-White, and G.M. Cole Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology Neurobiol. Aging 22 2001 993 1005
25. B.B. Fredholm, K. Battig, J. Holmen, A. Nehlig, and E.E. Zvartau Actions of caffeine in the brain with special reference to factors that contribute to its widespread use Pharmacol. Rev. 51 1999 83 133
26. C. Frezza, S. Cipolat, and L. Scorrano Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts Nat. Protoc. 2 2007 287 295
27. J.M. Fustin, H. Dardente, G.C. Wagner, D.A. Carter, J.D. Johnston, G.A. Lincoln, and D.G. Hazlerigg Egr1 involvement in evening gene regulation by melatonin Faseb J. 23 2009 764 773
28. B. Gong, O.V. Vitolo, F. Trinchese, S. Liu, M. Shelanski, and O. Arancio Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment J. Clin. Invest. 114 2004 1624 1634
29. C.A. Hansson Petersen, N. Alikhani, H. Behbahani, B. Wiehager, P.F. Pavlov, I. Alafuzoff, V. Leinonen, A. Ito, B. Winblad, E. Glaser, and M. Ankarcrona The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae Proc. Natl. Acad. Sci. U S A 105 2008 13145 13150
30. R. Hardeland Melatonin, mitochondrial electron flux, and leakage: recent findings and resolution of contradictory results Adv. Stud. Biol. 1 2009 207 230
31. S. Härtter, A. Nordmark, D.-M. Rose, L. Bertilsson, G. Tybring, and K. Laine Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity Br. J. Clin. Pharmacol. 56 2003 679 682
32. H. He, W. Dong, and F. Huang Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease Curr. Neuropharmacol. 8 2010 211 217
33. L.A. Horrigan, J.P. Kelly, and T.J. Connor Immunomodulatory effects of caffeine: friend or foe? Pharmacol. Ther. 111 2006 877 892
34. T. Ishrat, M.N. Hoda, M.B. Khan, S. Yousuf, M. Ahmad, M.M. Khan, A. Ahmad, and F. Islam Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT) Eur. Neuropsychopharmacol. 19 2009 636 647
35. B.L. Kagan, and J. Thundimadathil Amyloid peptide pores and the beta sheet conformation Adv. Exp. Med. Biol. 677 2010 150 167
36. U. Kilic, B. Yilmaz, M. Ugur, A. Yuksel, R.J. Reiter, D.M. Hermann, and E. Kilic Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia J. Pineal Res. 52 2012 228 235
37. D. Kim, M.D. Nguyen, M.M. Dobbin, A. Fischer, F. Sananbenesi, J.T. Rodgers, I. Delalle, J.A. Baur, G. Sui, S.M. Armour, P. Puigserver, D.A. Sinclair, and L.H. Tsai SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis Embo J. 26 2007 3169 3179
38. P.J. Kong, J.S. Byun, S.Y. Lim, J.J. Lee, S.J. Hong, K.J. Kwon, and S.S. Kim Melatonin induces Akt phosphorylation through melatonin receptor- and PI3K-dependent pathways in primary astrocytes Korean J. Physiol. Pharmacol. 12 2008 37 41
39. D. Liu, M. Pitta, J.H. Lee, B. Ray, D.K. Lahiri, K. Furukawa, M. Mughal, H. Jiang, J. Villarreal, R.G. Cutler, N.H. Greig, and M.P. Mattson The KATP channel activator diazoxide ameliorates amyloid-beta and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease J. Alzheimers Dis. 22 2010 443 457
40. F. Luchetti, B. Canonico, M. Betti, M. Arcangeletti, F. Pilolli, M. Piroddi, L. Canesi, S. Papa, and F. Galli Melatonin signaling and cell protection function Faseb J. 24 2010 3603 3624
41. T. MacKenzie, R. Comi, P. Sluss, R. Keisari, S. Manwar, J. Kim, R. Larson, and J.A. Baron Metabolic and hormonal effects of caffeine: randomized, double-blind, placebo-controlled crossover trial Metabolism 56 2007 1694 1698
42. L. Maia, and A. de Mendonca Does caffeine intake protect from Alzheimer's disease? Eur. J. Neurol. 9 2002 377 382
43. M. Manczak, T.S. Anekonda, E. Henson, B.S. Park, J. Quinn, and P.H. Reddy Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression Hum. Mol. Genet. 15 2006 1437 1449
44. M. Manczak, M.J. Calkins, and P.H. Reddy Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage Hum. Mol. Genet. 20 2011 2495 2509
45. M. Manczak, P. Mao, M.J. Calkins, A. Cornea, A.P. Reddy, M.P. Murphy, H.H. Szeto, B. Park, and P.H. Reddy Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons J. Alzheimers Dis. 20 Suppl. 2 2010 S609 S631
46. H.G. Mandel Update on caffeine consumption, disposition and action Food Chem. Toxicol. 40 2002 1231 1234
47. P. Mao, M. Manczak, M.J. Calkins, Q. Truong, T.P. Reddy, A.P. Reddy, U. Shirendeb, H.H. Lo, P.S. Rabinovitch, and P.H. Reddy Mitochondria-targeted catalase reduces abnormal APP processing, amyloid beta production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension Hum. Mol. Genet. 21 2012 2973 2990
48. M. Martin, M. Macias, J. Leon, G. Escames, H. Khaldy, and D. Acuna-Castroviejo Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria Int. J. Biochem. Cell. Biol. 34 2002 348 357
49. A.M. Mathes, D. Kubulus, L. Waibel, J. Weiler, P. Heymann, B. Wolf, and H. Rensing Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat Crit. Care Med. 36 2008 2863 2870
50. J.T. McKenna, M.A. Christie, B.A. Jeffrey, J.G. McCoy, E. Lee, N.P. Connolly, C.P. Ward, and R.E. Strecker Chronic ramelteon treatment in a mouse model of Alzheimer's disease Arch. Ital. Biol. 150 2012 5 14
51. S. McNulty, I.L. Schurov, P.J. Sloper, and M.H. Hastings Stimuli which entrain the circadian clock of the neonatal Syrian hamster in vivo regulate the phosphorylation of the transcription factor CREB in the suprachiasmatic nucleus in vitro Eur. J. Neurosci. 10 1998 1063 1072
52. W.W. Nichols, G.D. Curtis, and H.H. Johnston Choice of buffer anion for the assay of adenosine 5'-triphosphate using firefly luciferase Anal. Biochem. 114 1981 396 397
53. E. Nisoli, E. Clementi, C. Paolucci, V. Cozzi, C. Tonello, C. Sciorati, R. Bracale, A. Valerio, M. Francolini, S. Moncada, and M.O. Carruba Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide Science 299 2003 896 899
54. J.M. Olcese, C. Cao, T. Mori, M.B. Mamcarz, A. Maxwell, M.J. Runfeldt, L. Wang, C. Zhang, X. Lin, G. Zhang, and G.W. Arendash Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease J. Pineal Res. 47 2009 82 96
55. B.B. Otalora, N. Popovic, J. Gambini, M. Popovic, J. Vina, V. Bonet-Costa, R.J. Reiter, P.J. Camello, M.A. Rol, and J.A. Madrid Circadian system functionality, hippocampal oxidative stress, and spatial memory in the APPswe/PS1dE9 transgenic model of Alzheimer disease: effects of melatonin or ramelteon Chronobiol. Int. 29 2012 822 834
56. M. Pappolla, P. Bozner, C. Soto, H. Shao, N.K. Robakis, M. Zagorski, B. Frangione, and J. Ghiso Inhibition of Alzheimer beta-fibrillogenesis by melatonin J. Biol. Chem. 273 1998 7185 7188
57. A. Parachikova, K.N. Green, C. Hendrix, and F.M. LaFerla Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease PLoS One 5 2010 e14015
58. D. Puzzo, A. Staniszewski, S.X. Deng, L. Privitera, E. Leznik, S. Liu, H. Zhang, Y. Feng, A. Palmeri, D.W. Landry, and O. Arancio Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model J. Neurosci. 29 2009 8075 8086
59. H. Qosa, A.H. Abuznait, R.A. Hill, and A. Kaddoumi Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease J. Alzheimers Dis. 31 2012 151 165
60. J.F. Quinn, J.R. Bussiere, R.S. Hammond, T.J. Montine, E. Henson, R.E. Jones, and R.W. Stackman Jr. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice Neurobiol. Aging 28 2007 213 225
61. D. Resuehr, and J. Olcese Caloric restriction and melatonin substitution: effects on murine circadian parameters Brain Res. 1048 2005 146 152
62. K. Rezai-Zadeh, G.W. Arendash, H. Hou, F. Fernandez, M. Jensen, M. Runfeldt, R.D. Shytle, and J. Tan Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice Brain Res. 1214 2008 177 187
63. I.I. Sabry Caffeine injection in the dark phase prolongs the nocturnal rise in serotonin N-acetyltransferase activity and melatonin content in the pineal gland of male rats Endocr. Regul. 31 1997 207 210
64. M. Sanchez-Hidalgo, J.M. Guerrero Montavez, P. Carrascosa-Salmoral Mdel, C. Naranjo Gutierrez Mdel, P.J. Lardone, and C.A. de la Lastra Romero Decreased MT1 and MT2 melatonin receptor expression in extrapineal tissues of the rat during physiological aging J. Pineal Res. 46 2009 29 35
65. R.X. Santos, S.C. Correia, X. Wang, G. Perry, M.A. Smith, P.I. Moreira, and X. Zhu Alzheimer's disease: diverse aspects of mitochondrial malfunctioning Int. J. Clin. Exp. Pathol. 3 2010 570 581
66. R.X. Santos, S.C. Correia, X. Wang, G. Perry, M.A. Smith, P.I. Moreira, and X. Zhu A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease J. Alzheimers Dis. 20 Suppl. 2 2010 S401 S412
67. E.H. Sharman, N.D. Vaziri, Z. Ni, K.G. Sharman, and S.C. Bondy Reversal of biochemical and behavioral parameters of brain aging by melatonin and acetyl L-carnitine Brain Res. 957 2002 223 230
68. K.G. Sharman, E.H. Sharman, E. Yang, and S.C. Bondy Dietary melatonin selectively reverses age-related changes in cortical cytokine mRNA levels, and their responses to an inflammatory stimulus Neurobiol. Aging 23 2002 633 638
69. L. Shilo, H. Sabbah, R. Hadari, S. Kovatz, U. Weinberg, S. Dolev, Y. Dagan, and L. Shenkman The effects of coffee consumption on sleep and melatonin secretion Sleep Med. 3 2002 271 273
70. P. Shukla, A. Grazul-Bilska, and S.T. O'Rourke Melatonin inhibits NO-induced cGMP accumulation by increasing PDE5 phosphorylation in coronary arteries Faseb J. 24 Suppl. 957 2010 953
71. S.L. Siedlak, G. Casadesus, K.M. Webber, M.A. Pappolla, C.S. Atwood, M.A. Smith, and G. Perry Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease Free Radic. Res. 43 2009 156 164
72. G.B. Stokin, and L.S. Goldstein Axonal transport and Alzheimer's disease Annu. Rev. Biochem. 75 2006 607 627
73. G. Thinakaran, D.B. Teplow, R. Siman, B. Greenberg, and S.S. Sisodia Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus J. Biol. Chem. 271 1996 9390 9397
74. R.R. Tunstall, P. Shukla, A. Grazul-Bilska, C. Sun, and S.T. O'Rourke MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries J. Pharmacol. Exp. Ther. 336 2011 127 133
75. D. Ukena, M.T. Shamim, W. Padgett, and J.W. Daly Analogs of caffeine: antagonists with selectivity for A2 adenosine receptors Life Sci. 39 1986 743 750
76. C. Ursing, J. Wikner, K. Brismar, and S. Rojdmark Caffeine raises the serum melatonin level in healthy subjects: an indication of melatonin metabolism by cytochrome P450(CYP)1A2 J. Endocrinol. Invest. 26 2003 403 406
77. C.G. Vecsey, G.S. Baillie, D. Jaganath, R. Havekes, A. Daniels, M. Wimmer, T. Huang, K.M. Brown, X.Y. Li, G. Descalzi, S.S. Kim, T. Chen, Y.Z. Shang, M. Zhuo, M.D. Houslay, and T. Abel Sleep deprivation impairs cAMP signalling in the hippocampus Nature 461 2009 1122 1125
78. J.M. Wang, and C. Sun Calcium and neurogenesis in Alzheimer's disease Front. Neurosci. 4 2010 194
79. X. Wang, A. Sirianni, Z. Pei, K. Cormier, K. Smith, J. Jiang, S. Zhou, H. Wang, R. Zhao, H. Yano, J.E. Kim, W. Li, B.S. Kristal, R.J. Ferrante, and R.M. Friedlander The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity J. Neurosci. 31 2011 14496 14507
80. J.J. Webster, J.C. Chang, E.R. Manley, H.O. Spivey, and F.R. Leach Buffer effects on ATP analysis by firefly luciferase Anal. Biochem. 106 1980 7 11
81. K.P. Wright Jr., P. Badia, B.L. Myers, S.C. Plenzler, and M. Hakel Caffeine and light effects on nighttime melatonin and temperature levels in sleep-deprived humans Brain Res. 747 1997 78 84
82. M.N. Wu, K. Ho, A. Crocker, Z. Yue, K. Koh, and A. Sehgal The effects of caffeine on sleep in Drosophila require PKA activity, but not the adenosine receptor J. Neurosci. 29 2009 11029 11037
83. Y.H. Wu, J.N. Zhou, J. Van Heerikhuize, R. Jockers, and D.F. Swaab Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease Neurobiol. Aging 28 2007 1239 1247
84. D.Y. Yoo, W. Kim, C.H. Lee, B.N. Shin, S.M. Nam, J.H. Choi, M.H. Won, Y.S. Yoon, and I.K. Hwang Melatonin improves D-galactose-induced aging effects on behavior, neurogenesis, and lipid peroxidation in the mouse dentate gyrus via increasing pCREB expression J. Pineal Res. 52 2012 21 28
85. L. Yu, J.E. Coelho, X. Zhang, Y. Fu, A. Tillman, U. Karaoz, B.B. Fredholm, Z. Weng, and J.F. Chen Uncovering multiple molecular targets for caffeine using a drug target validation strategy combining A 2A receptor knockout mice with microarray profiling Physiol. Genomics 37 2009 199 210
86. R. Zeitlin, S. Patel, S. Burgess, G.W. Arendash, and V. Echeverria Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice Brain Res. 1417 2011 127 136